author-photo

Michael Aboud

ViiV Healthcare

48

Papers

796

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.

2021 Antimicrobial Agents and Chemotherapy
Show All
- Source
- Cite
- Save
Citations (0)
Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study)

2021 Hiv Medicine
Show All
- Source
- Cite
- Save
Citations (2)
Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis across three phase 3 studies.

2021 AIDS
Show All
- Source
- Cite
- Save
Citations (7)
MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO)

2021 Brazilian Journal of Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 96 weeks (TANGO study)

2020 Journal of the International AIDS Society
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study.

2020 Clinical Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (65)
Antiretroviral therapy and liver disorders in the OPERA® cohort:

2020 Therapeutic advances in drug safety
Show All
- Source
- Cite
- Save
Citations (0)
Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study)

2020 Journal of Infection and Public Health
Show All
- Source
- Cite
- Save
Citations (9)
Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

2020 Journal of Infection and Public Health
Show All
- Source
- Cite
- Save
Citations (11)
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies

2019 The Lancet HIV
Show All
- Source
- Cite
- Save
Citations (39)